Surviving and Thriving in Due Diligence – Major Transactions from the Perspective of Small Pharma

Life Sciences, Pharmaceutical, Commercialization & HEOR,
  • Wednesday, February 12, 2020

Innovation in drug discovery often starts in universities or with small enterprises. While the initial research and discovery are well within the purview of many university labs and small companies, advanced clinical development and commercialization are often well beyond the means of such entities. In order to bring drugs to market, smaller companies have to make enormous investments to build infrastructure (i.e. through public offerings), license their valuable pharmaceutical assets or simply sell the company to more established players who have the bandwidth for successful commercialization. All three of these scenarios may occur in the lifecycle of a successful company.

The process by which an initial public offering (IPO), license, or sale (i.e. acquisition) takes place is through what is termed “due diligence.” Due diligence is a general term and the definition from Investopedia is apt – “Due diligence refers to the research done before entering into an agreement or a financial transaction with another party.” Such research includes financial analysis, clinical efficacy, human resource investigations and intellectual property. With pharmaceutical assets, the patent estate often comprises the bulk of the intellectual property value and, therefore, is typically a key focus in due diligence.

Patents provide exclusionary rights without which there is often insufficient barrier to competition to warrant investment. As a result, sophisticated investors and acquirers devote substantial resources to perform due diligence on patent assets they are considering for deal-making. This webinar will take the attendees through the due diligence process through the eyes of a small company interested in making a transaction with its intellectual property. The featured speaker will discuss the different classes of patents one finds in pharmaceuticals along with the typical value drivers for each class of patent. Basic due diligence concepts around inventorship, chain of title and scope of filing will be addressed. In addition, the speaker will also dig a bit deeper into the patent concepts of validity, infringement and design-arounds that often are the focus of due diligence inquiries. 


Eyal Barash, Barash Law, LLC

Eyal Barash, JD, Attorney at Law, Barash Law, LLC

Eyal Barash has been a practicing patent attorney for over 20 years. He obtained a JD degree from Northwestern University in 1997 and a Master’s degree in Chemistry from the University of California, Berkeley in 1994. He also earned a Bachelor of Science degree in Chemistry and a Bachelor of Arts degree in History from Indiana University, both in 1991. Mr. Barash practiced in Washington, DC at a large patent boutique until 2005 when he returned to Indiana and made his home in West Lafayette. His portfolio of clients includes startups and more mature companies, many of them in the life sciences. He acts as a “roving” in-house counsel to many such companies and has been involved in numerous patent due diligences on both the buy and sell side.

Message Presenter

Who Should Attend?

This webinar will appeal to senior-level executives such as CEOs, CFOs, VPs of business and in-house counsel working at:

  • Small to medium pharma companies
  • Law firms with corporate transaction teams

What You Will Learn

Attendees will gain insights into: 

  • An overview of the due diligence process from a small company’s point of view
  • Different classes of pharmaceutical patents
  • Value drivers for each class of patent
  • Due diligence concepts around inventorship, chain of title and scope of filing
  • Common due diligence inquiries (e.g. patent validity, infringement, design-arounds) 

Xtalks Partner

Barash Law LLC

For startups and other early-stage ventures, Eyal acts as general counsel and manages and develops intellectual property portfolios, negotiates license agreements, and leads due diligence activities when looking to partner intellectual property assets. For more mature firms, Eyal often acts as a consultant where he specializes in drug repositioning including 505(b)(2) strategies for small molecule pharmaceutical development.

Eyal worked at a large intellectual property law firm in Washington DC for 8 years and was chief patent counsel and general counsel to a small pharmaceutical company for 4 years prior to starting Barash Law in 2009. After obtaining Bachelor degrees in chemistry and history from Indiana University, Eyal received a Masters degree in physical chemistry from Berkeley with a focus on solid-state NMR. He was awarded his law degree from Northwestern University in 1997.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account